Drug Profile
Research programme: parasitic infection therapeutics - Merck/DNDi
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Merck & Co
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease; Leishmaniasis
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Chagas-disease in Switzerland
- 28 May 2021 No recent reports of development identified for research development in Chagas-disease in USA
- 28 May 2021 No recent reports of development identified for research development in Leishmaniasis in Switzerland